INCY insider transaction filings
INCYTE CORP — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-17. Screen INCY transaction legs live →
Insider transaction summary — last 90 days
2026-06-25 to 2026-09-23, from the filings listed below: 31 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 22 legs across 10 filings by 4 insiders — 152,718 shares, $18,199,079 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 90.
- Largest priced transaction: sale of 28,237 shares @ $113.05 ($3,192,193) by Stein Steven H, filed 2026-07-16.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| CAGNONI PABLO J — President, Global Head of R&D | 7 | — | 6 legs · 71,350 sh · $8,657,810 | 13 |
| Mayes Patrick A — EVP & Chief Scientific Officer | 5 | — | 13 legs · 50,161 sh · $6,008,022 | 40 |
| Stein Steven H — CMO & Head of Late-Stage Dev. | 3 | — | 2 legs · 30,114 sh · $3,407,541 | 6 |
| Issa Mohamed Khairie — EVP, Head of U.S. Commercial | 2 | — | 1 leg · 1,093 sh · $125,706 | 4 |
| Tray Thomas — Principal Accounting Officer | 3 | — | — | 5 |
| Basi Ramitpal K — EVP, Human Resources | 2 | — | — | 4 |
| Meury William — Chief Executive Officer, Director | 2 | — | — | 4 |
| Gardner David H — EVP, Chief Strategy Officer | 1 | — | — | 3 |
| Hoffman Richard A. — EVP & General Counsel | 1 | — | — | 3 |
| BAKER BROS. ADVISORS LP — Director, 10% owner & 667, L.P. — Director, 10% owner & Baker Bros. Advisors (GP) LLC — Director, 10% owner & Baker Brothers Life Sciences LP — Director, 10% owner & BAKER FELIX — Director, 10% owner & BAKER JULIAN — Director, 10% owner | 1 | — | — | 2 |
+4 more insiders in the window, not shown — every filing appears in the table below.
Recent Form 4 filings — INCYTE CORP
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | CAGNONI PABLO J — President, Global Head of R&D | Option exercise (M): 2,957 @ $61.76 · Option exercise (M): 4,551 @ $61.18 · Option exercise (M): 6,477 @ $64.25 · Option exercise (M): 9,233 @ $71.93 · Sale (S): 9,233 @ $120.50 · Sale (S): 13,985 @ $120.49 · +4 more | EDGAR |
| 2026-08-27 | 4 | Basi Ramitpal K — EVP, Human Resources | Tax withholding (F): 504 @ $129.72 | EDGAR |
| 2026-08-20 | 4 | CAGNONI PABLO J — President, Global Head of R&D | Sale (S): 10,801 @ $125.56 | EDGAR |
| 2026-08-14 | 4 | CAGNONI PABLO J — President, Global Head of R&D | Sale (S): 10,803 @ $120.04 | EDGAR |
| 2026-08-07 | 4 | Mayes Patrick A — EVP & Chief Scientific Officer | Option exercise (M): 2,207 @ $106.47 · Sale (S): 2,207 @ $123.99 · Option exercise (M): 2,207 (derivative) @ $0 | EDGAR |
| 2026-08-07 | 4 | CAGNONI PABLO J — President, Global Head of R&D | Sale (S): 10,640 @ $122.69 | EDGAR |
| 2026-08-04 | 4 | CAGNONI PABLO J — President, Global Head of R&D | Sale (S): 15,888 @ $119.70 | EDGAR |
| 2026-08-04 | 4 | Mayes Patrick A — EVP & Chief Scientific Officer | Option exercise (M): 2,918 @ $61.18 · Option exercise (M): 2,284 @ $64.25 · Option exercise (M): 2,709 @ $61.76 · Option exercise (M): 3,148 @ $68.62 · Option exercise (M): 2,072 @ $71.93 · Option exercise (M): 9,459 @ $72.27 · +38 more | EDGAR |
| 2026-07-27 | 4 | Heeson Lee — EVP, Head of Incyte Intl | Grant/award (A): 15,423 (derivative) @ $0 · Grant/award (A): 13,498 (derivative) @ $0 | EDGAR |
| 2026-07-27 | 4 | Morrissey Michael James — EVP, Head of Tech. Operations | Grant/award (A): 6,426 (derivative) @ $0 · Grant/award (A): 8,999 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Hoffman Richard A. — EVP & General Counsel | Grant/award (A): 7,395 @ $0 · Grant/award (A): 18,487 (derivative) @ $0 · Grant/award (A): 31,923 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Gardner David H — EVP, Chief Strategy Officer | Grant/award (A): 7,395 @ $0 · Grant/award (A): 18,487 (derivative) @ $0 · Grant/award (A): 31,923 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Basi Ramitpal K — EVP, Human Resources | Grant/award (A): 4,991 @ $0 · Grant/award (A): 12,479 (derivative) @ $0 · Grant/award (A): 21,548 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Mayes Patrick A — EVP & Chief Scientific Officer | Grant/award (A): 5,916 @ $0 · Grant/award (A): 14,790 (derivative) @ $0 · Grant/award (A): 25,538 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Issa Mohamed Khairie — EVP, Head of U.S. Commercial | Sale (S): 1,093 @ $115.01 · Grant/award (A): 7,857 @ $0 · Grant/award (A): 19,643 (derivative) @ $0 · Grant/award (A): 33,918 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Tray Thomas — Principal Accounting Officer | Grant/award (A): 2,834 @ $0 · Grant/award (A): 4,079 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Stein Steven H — CMO & Head of Late-Stage Dev. | Sale (S): 1,877 @ $114.73 · Grant/award (A): 9,798 @ $0 · Grant/award (A): 24,496 (derivative) @ $0 · Grant/award (A): 42,298 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Meury William — Chief Executive Officer, Director | Grant/award (A): 26,807 @ $0 · Grant/award (A): 80,421 (derivative) @ $0 · Grant/award (A): 77,148 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | CAGNONI PABLO J — President, Global Head of R&D | Grant/award (A): 13,403 @ $0 · Grant/award (A): 33,508 (derivative) @ $0 · Grant/award (A): 57,861 (derivative) @ $0 | EDGAR |
| 2026-07-16 | 4 | Mayes Patrick A — EVP & Chief Scientific Officer | Tax withholding (F): 437 @ $114.88 · Tax withholding (F): 1,512 @ $115.09 | EDGAR |
| 2026-07-16 | 4 | Issa Mohamed Khairie — EVP, Head of U.S. Commercial | Tax withholding (F): 1,099 @ $115.09 | EDGAR |
| 2026-07-16 | 4 | Tray Thomas — Principal Accounting Officer | Tax withholding (F): 692 @ $114.88 · Tax withholding (F): 1,098 @ $115.09 | EDGAR |
| 2026-07-16 | 4 | Stein Steven H — CMO & Head of Late-Stage Dev. | Tax withholding (F): 21,830 @ $114.88 · Sale (S): 28,237 @ $113.05 · Tax withholding (F): 3,088 @ $115.09 | EDGAR |
| 2026-07-16 | 4 | CAGNONI PABLO J — President, Global Head of R&D | Tax withholding (F): 17,969 @ $114.88 · Tax withholding (F): 4,950 @ $115.09 | EDGAR |
| 2026-07-07 | 4 | Mayes Patrick A — EVP & Chief Scientific Officer | Tax withholding (F): 350 @ $116.86 | EDGAR |
| 2026-07-07 | 4 | Tray Thomas — Principal Accounting Officer | Tax withholding (F): 477 @ $116.86 | EDGAR |
| 2026-07-07 | 4 | Stein Steven H — CMO & Head of Late-Stage Dev. | Tax withholding (F): 2,177 @ $116.86 | EDGAR |
| 2026-07-07 | 4 | Meury William — Chief Executive Officer, Director | Tax withholding (F): 4,779 @ $116.86 | EDGAR |
| 2026-07-02 | 4 | Clancy Paul J — Director | Grant/award (A): 252 @ $113.36 | EDGAR |
| 2026-07-02 | 4 | HARRIGAN EDMUND — Director | Grant/award (A): 255 @ $113.36 | EDGAR |
| 2026-07-02 | 4 | BAKER BROS. ADVISORS LP — Director, 10% owner 667, L.P. — Director, 10% owner Baker Bros. Advisors (GP) LLC — Director, 10% owner Baker Brothers Life Sciences LP — Director, 10% owner BAKER FELIX — Director, 10% owner BAKER JULIAN — Director, 10% owner | Grant/award (A): 400 @ $0 · Grant/award (A): 400 @ $0 | EDGAR |
| 2026-06-10 | 4 | High Katherine A — Director | Grant/award (A): 1,642 @ $0 · Grant/award (A): 6,111 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Clancy Paul J — Director | Grant/award (A): 1,642 @ $0 · Grant/award (A): 6,111 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | FOUSE JACQUALYN A — Director | Grant/award (A): 1,642 @ $0 · Grant/award (A): 6,111 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | BIENAIME JEAN JACQUES — Director | Grant/award (A): 1,642 @ $0 · Grant/award (A): 6,111 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | BRAWLEY OTIS W — Director | Grant/award (A): 1,642 @ $0 · Grant/award (A): 6,111 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | HARRIGAN EDMUND — Director | Grant/award (A): 1,642 @ $0 · Grant/award (A): 6,111 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | BAKER BROS. ADVISORS LP — Director, 10% owner 667, L.P. — Director, 10% owner Baker Bros. Advisors (GP) LLC — Director, 10% owner Baker Brothers Life Sciences LP — Director, 10% owner BAKER FELIX — Director, 10% owner BAKER JULIAN — Director, 10% owner | Grant/award (A): 1,642 @ $0 · Grant/award (A): 1,642 @ $0 · Grant/award (A): 6,111 (derivative) @ $0 · Grant/award (A): 6,111 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Tray Thomas — Principal Accounting Officer | Option exercise (M): 2,639 @ $83.83 · Sale (S): 2,639 @ $100 · Option exercise (M): 2,639 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | CAGNONI PABLO J — President, Global Head of R&D | Tax withholding (F): 25,469 @ $95.59 | EDGAR |
| 2026-05-28 | 4 | Tray Thomas — Principal Accounting Officer | Sale (S): 2,051 @ $97.35 | EDGAR |
| 2026-05-28 | 4 | BIENAIME JEAN JACQUES — Director | Option exercise (M): 15,000 @ $84.53 · Tax withholding (F): 13,059 @ $97.10 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Clancy Paul J — Director | Option exercise (M): 15,000 @ $84.53 · Sale (S): 15,000 @ $94.93 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4/A | Stein Steven H — CMO & Head of Late-Stage Dev. | Grant/award (A): 44,124 @ $0 | EDGAR |
| 2026-05-20 | 4/A | CAGNONI PABLO J — President, Global Head of R&D | Grant/award (A): 31,517 @ $0 | EDGAR |
| 2026-05-11 | 4 | BAKER BROS. ADVISORS LP — Director, 10% owner 667, L.P. — Director, 10% owner Baker Bros. Advisors (GP) LLC — Director, 10% owner Baker Brothers Life Sciences LP — Director, 10% owner BAKER FELIX — Director, 10% owner BAKER JULIAN — Director, 10% owner | Option exercise (M): 15,000 @ $84.53 · Option exercise (M): 15,000 @ $84.53 · Option exercise (M): 15,000 (derivative) @ $0 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-05-06 | 4 | Upadhyay Suketu — EVP & Chief Financial Officer | Grant/award (A): 26,343 @ $0 · Grant/award (A): 38,429 (derivative) @ $0 · Grant/award (A): 13,171 (derivative) @ $0 | EDGAR |
| 2026-04-21 | 4 | CAGNONI PABLO J — President, Global Head of R&D | Option exercise (M): 6,077 @ $64.25 · Option exercise (M): 12,590 @ $71.93 · Sale (S): 18,667 @ $96.50 · Option exercise (M): 6,077 (derivative) @ $0 · Option exercise (M): 12,590 (derivative) @ $0 | EDGAR |
| 2026-04-17 | 4 | Meury William — Chief Executive Officer, Director | Option exercise (M): 125,000 @ $0 | EDGAR |
| 2026-04-17 | 4 | CAGNONI PABLO J — President, Global Head of R&D | Grant/award (A): 27,892 @ $0 | EDGAR |
Recent 8-K events — INCYTE CORP
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-31 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-07-28 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-06 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-06-09 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-08 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-04-28 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2026-03-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-26 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-06 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=INCY returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →